Topic

Drug-eluting Stent


Abbott posts slight Q2 gains, bolstered by 9% increase in stent sales

Top Stories | Wednesday, July 21 2010
Abbott has reported double-digit net sales in the 2010 second quarter, which ended June 30, but only saw net earnings of 0.3 percent over the 2009 second quarter.
 

Bos Sci’s Q2 takes hit from defib sales halt; stent sales drop too

Financial News | Wednesday, July 21 2010
Boston Scientific has filed financial results for its second quarter, ending June 30, which were adversely affected by the FDA's halt on defibrillator systems, along with falling stent sales.
 

Liang becomes new CEO, prez at Medrad

Executive Announcements | Thursday, June 03 2010
Bayer Medical Care has appointed Samuel M. Liang as incoming president and CEO of Medrad, a cardiovascular device company, upon the retirement of John Friel later this year. Liang will succeed Friel as of July 1.
 

Abbott’s income dips in Q1, sales impacted by healthcare reform

Top Stories | Wednesday, April 21 2010
Abbott has reported a decrease in net earnings, despite a sales increase for its financial results for the 2010 first quarter, which ended March 31.
 

SIR: Drug-eluting stents emerge as option for critical limb ischemia

Conference News | Tuesday, March 16 2010
Interventional radiologists have found that a subgroup of patients with critical limb ischemia, the most severe form of peripheral arterial disease (PAD), may avoid amputation through the use of drug-eluting stents on the smaller arteries below the knee, according to a study released at this week’s Society of Interventional Radiology's (SIR) Annual Scientific Meeting in Tampa, Fla.
 

PNAS: Nanoparticles could eliminate drug-eluting stents

Clinical Studies | Tuesday, January 19 2010
Researchers at Massachusetts Institute of Technology and Harvard Medical School have built targeted nanoparticles that can cling to artery walls and slowly release medicine, which could be an alternative to drug-eluting stents in some patients with cardiovascular disease, according to research published in the Jan. 18 issue of the Proceedings of the National Academy of Sciences.
 

Abbott launches Xience Prime in Europe, other international markets

New Products | Monday, August 31 2009
Abbott has launched its Xience Prime everolimus-eluting coronary stent system for the treatment of coronary artery disease at the European Society of Cardiology (ESC) Congress this week in Barcelona, Spain. 
 

Radiologist continues stent infringement suits, sets sights on Abbott

Top Stories | Thursday, August 27 2009
New Jersey radiologist Bruce N. Saffran, MD, who was awarded about $500 million in a 2008 patent infringement case against Boston Scientific, filed suit Monday in the U.S. District Court for the Eastern District of Texas over Abbott's Xience V everolimus-eluting coronary stent.
 

Health Canada gives thumbs up to Xience V

Regulatory News | Wednesday, August 26 2009
Abbott has received approval from Health Canada for the Xience V everolimus-eluting coronary stent system for the treatment of coronary artery disease.
 

Cook, Angiotech peripheral DES gains CE Mark

Regulatory News | Tuesday, August 11 2009
Cook Medical and Angiotech Pharmaceuticals received CE Mark approval Monday for their polymer-free Zilver PTX drug-eluting peripheral stent to treat blockages in the legs caused by peripheral arterial disease.
 

Boston Sci sees Q2 income uptick on strong stent, CRM sales

Financial News | Tuesday, August 04 2009
Boston Scientific has reported positive financial earnings for its fiscal 2009 second quarter, which ended June 30. The Natick, Mass.-based medical device company booked a net income of $158 million this quarter, compared with $98 million in the second quarter of 2008.
 

Abbott dips 2.6% in Q2; stent sales remain strong

Financial News | Wednesday, July 15 2009
Abbott posted its financial results for the second quarter, which ended June 30, showing a 2.6 percent decrease in net earnings--to $1.29 billion from  $1.32 billion in the same period last year.
 

Abbott nets CE Mark for new Xience Prime DES

Regulatory News | Tuesday, June 23 2009
Abbott has received CE Mark for its next-generation Xience Prime everolimus-eluting coronary stent system for the treatment of coronary artery disease. The company plans to launch Xience Prime in a varied size matrix, with lengths up to 38 mm, in the third quarter across Europe.
 

FDA clears Bos Sci stent for 2.25mm heart vessels

Regulatory News | Wednesday, May 27 2009
Boston Scientific has received approval from the FDA to market its Taxus Liberte Atom paclitaxel-eluting coronary stent system, a drug-eluting stent (DES) designed for treating small coronary vessels, as small as 2.25 mm in diameter.
 

SIR: Interventional rads save limbs with drug-eluting stents

Conference News | Tuesday, March 10 2009
Treating critical limb ischemia in peripheral arterial disease (PAD) patients with below-the-knee angioplasty is thwarted by restenosis, the need for repeat treatments and the continued progression of atherosclerotic disease, leading to tissue death and amputation. However, interventional radiologists have found that drug-eluting stents (DES) lessen the rate of repeat procedures to open these small arteries, according to results presented at the Society of Interventional Radiology (SIR) annual meeting in San Diego this week.
 
Web Exclusives

Feature: U.S. needs national strategy to curb imaging overutilization

Medical imaging overutilization--a growing concern in the U.S.--exposes patients to unnecessary radiation, while also adding to rising healthcare costs, according to a study published online Aug. 24 in Radiology. In an interview, William R. Hendee, PhD, lead author, reviewed various methods by which medical imaging could be curtailed.

Radiology: Prelim study shows CE breast CT outperforms CT, mammo

Dedicated contrast-enhanced (CE) breast CT delivered significantly improved conspicuity of malignant breast lesions, including ductal carcinoma in situ (DCIS), compared with unenhanced breast CT and mammography, according to a study published in the September issue of Radiology.

Radiology: Rad role may evolve as image-guided biopsies trend up

CT, ultrasound and MRI have helped shift biopsy techniques away from more invasive approaches toward image-guided percutaneous techniques, according to a study published in the September issue of Radiology. The trend toward less-invasive approaches translates into enhanced safety and efficiency and could lead to more interaction between patients and radiologists.

CMS Webinar: Incentive payments to offset EHR adoption, not reimburse

The Centers for Medicare & Medicaid Services’ (CMS) EHR incentive payments are not considered reimbursement for money expended on EHR technology, but are intended to offset the cost associated with adoption and ongoing meaningful use, according to CMS during an Aug. 12 webinar.

CMS webinar: Eligible professionals can expect EHR incentives in 2011

Funding incentives for EHR use is the main goal of the Centers for Medicare & Medicaid Services' (CMS) meaningful use initiative, and there are incentive programs for both hospitals and eligible professionals, according to Elizabeth Holland, health insurance specialist at the Department of Health and Human Services, who spoke during a CMS-sponsored webinar Aug. 8.

Webinar: Stage 1 of meaningful use is for quality reporting acclimation

Stage 1 requirements for meaningful use incentives aim to strike a balance between the overall goal of EHR use and widespread adoption, while avoiding added work, said Jonathan Teich, MD, PhD, chief medical informatics officer at Elsevier Health Services, during a HIMSS webinar titled “Meaningful Use: Safety and Quality of Care.”

PORTALS

Advanced Visualization

Molecular Imaging

Integration Tools & Interoperability

More Portal Topics